WallStSmart

CAMP4 THERAPEUTICS CORPORATION (CAMP)vsNovartis AG ADR (NVS)

VS

CAMP

CAMP4 THERAPEUTICS CORPORATION

NASDAQ

$4.25

-2.07%

HEALTHCARE · Cap: $266.70M

NVS

Novartis AG ADR

NYSE

$137.16

-0.23%

HEALTHCARE · Cap: $260.70B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 1344611% more annual revenue ($56.69B vs $4.22M). NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).

CAMP

Avoid

25

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -3.49

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CAMP.

NVSSignificantly Overvalued (-47.0%)

Margin of Safety

-47.0%

Fair Value

$93.29

Current Price

$137.16

$43.87 premium

UndervaluedFair: $93.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CAMP2 strengths · Avg: 9.0/10
Debt/EquityHealth
-3.4210/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
18.8%8/10

18.8% revenue growth

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$260.70B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability
34.6%10/10

Strong operational efficiency at 34.6%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

Areas to Watch

CAMP4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$266.70M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

PEG RatioValuation
3.222/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : CAMP

The strongest argument for CAMP centers on Debt/Equity, Revenue Growth. Revenue growth of 18.8% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.

Bear Case : CAMP

The primary concerns for CAMP are EPS Growth, Market Cap, Profit Margin.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

CAMP profiles as a growth stock while NVS is a value play — different risk/reward profiles.

CAMP is growing revenue faster at 18.8% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (51/100 vs 25/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CAMP4 THERAPEUTICS CORPORATION

HEALTHCARE · BIOTECHNOLOGY · USA

CalAmp Corp. The company is headquartered in Irvine, California.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Compare with Other BIOTECHNOLOGY Stocks

CAMP vs VRTXCAMP vs REGNCAMP vs ARGXCAMP vs MRNACAMP vs RVMDNVS vs VRTXNVS vs REGNNVS vs ARGXNVS vs MRNANVS vs RVMD

Want to dig deeper into these stocks?

Full CAMP Analysis →Full NVS Analysis →